Clinical evaluation of pimecrolimus eye drops for treatment of canine keratoconjunctivitis sicca: A comparison with cyclosporine A

Ron Ofri*, George N. Lambrou, Ingrid Allgoewer, Uwe Graenitz, Teresa M. Pena, Bernhard M. Spiess, Elisabeth Latour

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

25 Scopus citations

Abstract

The aim of this study was to evaluate the efficacy of pimecrolimus oil-based eye drops in alleviating the clinical signs of keratoconjunctivitis sicca (KCS) in dogs and to compare the efficacy with that of cyclosporine A (CsA) ointment. An open-label, multicenter study enrolling 44 dogs previously untreated with CsA was conducted. Dogs were randomly assigned to a treatment group and medicated twice daily for 8 weeks. After that time the mean increase (±SEM) in the Schirmer tear test was 9.2 ± 1.6 mm/min in the pimecrolimus group and 5.8 ± 1.1 mm/min in the CsA group (P = 0.085). The improvement in clinical signs of inflammation in eyes treated with pimecrolimus was significantly greater than in eyes treated with CsA (P = 0.02). The results show that 1% pimecrolimus oily eye drops are as safe as and more effective than CsA ointment in controlling KCS in dogs.

Original languageAmerican English
Pages (from-to)70-77
Number of pages8
JournalVeterinary Journal
Volume179
Issue number1
DOIs
StatePublished - Jan 2009

Bibliographical note

Funding Information:
This study was supported entirely by Novartis Institutes for BioMedical Research, Basel, Switzerland. The authors do not have any financial interest in the drugs tested. The authors thank Barry Kapik, John Koester and Kim Truett for assistance with statistical analyses.

Keywords

  • Cyclosporine A
  • Dog
  • Dry eye
  • Keratoconjunctivitis sicca
  • Pimecrolimus

Fingerprint

Dive into the research topics of 'Clinical evaluation of pimecrolimus eye drops for treatment of canine keratoconjunctivitis sicca: A comparison with cyclosporine A'. Together they form a unique fingerprint.

Cite this